Evaluation of the effect of RIPC (remote ischemic preconditioning) on migrane headache and Brain metabolites in MRS (magnetic resonance spectroscopy) and qEEG indices of migraine patients a pilot study

Not Applicable

Conditions: Migraine.
Chronic migraine without aura, intractable, with status migrainosus
G43.711

Registration Number: IRCT20210212050334N4

Lead Sponsor: Rasht University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 30

Inclusion Criteria

Patient have at least 5 headache attacks lasting 4–72 hours (without treatment or unsuccessful treatment)
Age range from 18 to 50 years
The onset of migraines before menopause
The ability of patients to distinguish migraine headaches from other conditions
The patient's ability to fill out questionnaire
Both male and female gender
Informed consent

Exclusion Criteria

Underlying diseases, history of chronic diseases or kidney, liver, cardiovascular, renal, pulmonary diseases, any malignancy, autoimmunity, diabetes mellitus
Convulsions
Menopause
Head and neck trauma
Asthenic damage
Mental disorders and major depression according to DSM4
Botox injection in the last 6 months
Pregnancy and lactation
Non-migraine headaches such as tension headaches that occur more than 12 times a month and cervicogenic
Drug and alcohol dependence during the 1 year prior to the study
Migraine with aura
History of off pump surgery
Severe hypertension higher than 160/90 mm / hg
Rheumatism

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glutamate. Timepoint: Days 0 and 60. Method of measurement: Magnetic resonance spectroscopy (MRS) test.;N-acetyl aspartate. Timepoint: Days 0 and 60. Method of measurement: MRS test.;Choline. Timepoint: Days 0 and 60. Method of measurement: MRS test.;Creatine. Timepoint: Days 0 and 60. Method of measurement: MRS test.;Myoinositol. Timepoint: Days 0 and 60. Method of measurement: MRS test.;GABA. Timepoint: Days 0 and 60. Method of measurement: MRS test.;Glutamate/Creatine. Timepoint: Days 0 and 60. Method of measurement: Math.;NAA/Cr. Timepoint: Days 0and 60. Method of measurement: Math.;Choline/Cr. Timepoint: Days 0 and 60. Method of measurement: Math.;Myoinisitol/Cr. Timepoint: Days 0and 60. Method of measurement: Math.;Absolute frequency bands. Timepoint: Days 0 and 60. Method of measurement: Qeeg.;Relative frequency bands. Timepoint: days 0and 60. Method of measurement: Qeeg.;Coherence. Timepoint: Days 0 and 60. Method of measurement: Qeeg analyze.

Secondary Outcome Measures